Bio-Techne (TECH) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bio-Techne Releases First Quarter Fiscal 2016 Results
October 28, 2015 7:01 AM EDTMINNEAPOLIS, Oct. 28, 2015 /PRNewswire/ --Â Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2015.
First Quarter 2016 Snapshot
Increased first quarter revenue by 4% to $112.4 million. Delivered first quarter adjusted earnings of $29.4 million, down 10% from the prior year due to FX headwinds and the timing of acquisitions in the prior year. Generated operating cash flow of $31.8 million. Continued the trend of double-digit growth in China. Achieved solid growth in the BioPharma end-markets, with a return to... MoreBio-Techne Certifies over 1,000 Antibodies for Simple Western
October 26, 2015 8:30 AM EDTMINNEAPOLIS, Oct. 26, 2015 /PRNewswire/ -- Bio-Techne Corporation announced today that its R&D Systems®, Novus Biologicals®, and ProteinSimple® brands have collaborated to certify over 1,000 antibodies for the Simple Western platform. This milestone demonstrates the power of combining premier reagent providers with innovative protein analysis systems.  The combination will enable scientists to easily transition to quantifying proteins with the Simple Western system from the tedious and semi-quantitative Western Blot method in use today.Â
"Antibody validation and reproducibility are a continuing concern in our industry," says Dr. Birte Aggeler, Director of Antibody Development at R&D Systems. "The Simple Western... More
